Canada markets closed

ARCA biopharma, Inc. (ABIO)

NasdaqCM - NasdaqCM Real Time Price. Currency in USD
Add to watchlist
2.25000.0000 (0.00%)
At close: 04:00PM EST
2.2700 +0.02 (+0.89%)
After hours: 07:53PM EST
Full screen
Trade prices are not sourced from all markets
Previous Close2.2500
Open2.2800
Bid2.2600 x 1000
Ask2.2700 x 800
Day's Range2.1800 - 2.3280
52 Week Range2.1700 - 5.5000
Volume611,411
Avg. Volume412,712
Market Cap32.423M
Beta (5Y Monthly)2.50
PE Ratio (TTM)N/A
EPS (TTM)N/A
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
All
News
  • GlobeNewswire

    ARCA biopharma Announces Completion of Enrollment in Phase 2b ASPEN-COVID-19 Clinical Trial Evaluating rNAPc2 as a Potential Treatment for Patients Hospitalized with COVID-19

    Dr. Bristow Dr. Michael Bristow, President and CEO, ARCA biopharma, Inc. Topline readout of clinical trial results anticipated in first quarter of 2022 WESTMINSTER, Colo., Dec. 02, 2021 (GLOBE NEWSWIRE) -- ARCA biopharma, Inc. (Nasdaq: ABIO), a biopharmaceutical company applying a precision medicine approach to developing targeted therapies for cardiovascular diseases, today announced that enrollment has been completed in ASPEN-COVID-19, the Phase 2b clinical trial evaluating rNAPc2 as a potenti

  • GlobeNewswire

    ARCA biopharma to Present at the Q4 Virtual Investor Summit on November 17th

    WESTMINSTER, Colo., Nov. 09, 2021 (GLOBE NEWSWIRE) -- ARCA biopharma, Inc. (Nasdaq: ABIO), a biopharmaceutical company applying a precision medicine approach to developing genetically targeted therapies for cardiovascular diseases, today announced that Tom Keuer, Chief Operating Officer, will present at the Q4 Virtual Investor Summit being held November 16-17, 2021. ARCA is scheduled to present on Wednesday, November 17, 2021 at 4:15 PM ET. Management will be available for one-on-one meetings to

  • GlobeNewswire

    ARCA biopharma Announces Third Quarter 2021 Financial Results and Provides Corporate Update

    Dr. Bristow Dr. Michael Bristow, President and CEO, ARCA biopharma, Inc. On-going Phase 2b clinical trial (ASPEN-COVID-19) evaluating rNAPc2 as a potential treatment for COVID-19DSMC interim analysis of safety and efficacy data from ASPEN-COVID-19 completed with recommendation to continue trial to completion with no modificationsTopline data anticipated in first quarter of 2022Cash and cash equivalents of $58.3 million at September 30, 2021, sufficient to fund operations through 2022 WESTMINSTER